三尖瓣介入治疗进展

Progress of tricuspid valve interventional treatment

三尖瓣关闭不全(tricuspid regurgitation,TR)是最常见的心脏瓣膜疾病之一,患者基数庞大。疾病的隐匿性使得TR患者长期未受到重视,但随着严重TR患者表现出累及全身多脏器的临床症状、较差的生活质量以及较低的生存率,TR逐步受到关注。当前对重度TR的药物治疗效果不佳,且患者常常由于高龄、合并症等手术禁忌而无法得到有效治疗。近年来,经导管三尖瓣介入技术(transcatheter tricuspid valve interventions,TTVI)蓬勃发展,逐渐在临床上得到应用和推广。本文主要总结经导管介入治疗器械及其相关临床研究的安全性和有效性数据。

Tricuspid regurgitation(TR)is a common heart valve disease with a large amount of patients.Since the stealthiness of TR,patients have been kept out of the spotlight for a long time.However,due to symptoms related to multiple organs,poor quality of life,and low survival rates in patients with severe TR,TR is attracting more attention.Current pharmacologic treatment for severe TR is ineffective,and patients are frequently undertreated due to surgical contraindications such as advanced age and comorbidities.Transcatheter tricuspid valve interventions(TTVI)have grown in popularity in recent years,and they are now widely used and promoted in clinical practice.This article summarizes the safety and efficacy data for transcatheter interventional devices and related clinical trials.